Supira Medical, Inc.

Supira Medical, Inc. is a US-based company that develops innovative percutaneous ventricular assist devices (pVADs) to support patients during high-risk cardiac procedures, enhancing their safety and recovery. Founded in 2012 in the US, Supira Medical, Inc. specializes in advanced percutaneous ventricular assist devices, focusing on enhancing cardiac care.

The company has undergone a strategic focus on the development of pVADs to meet the needs of high-risk cardiac patients. The CEO, Nitin Salunke, leads the company, which has completed 7 funding deals, including a Series E funding round in March 2025, raising USD 120. 00 mn from investors such as Novo Holdings and Qatar Investment Authority, among others. This funding round marked a significant milestone for the company as it raised the total amount of USD 120.

00 mn to date. Supira Medical, Inc. specializes in the development of next-generation percutaneous ventricular assist devices (pVADs) tailored for temporary mechanical support during high-risk percutaneous coronary interventions (PCI) and cardiogenic shock (CS). Their flagship product is a low-profile, high-flow pVAD designed to assist the heart's native pumping action, facilitating critical interventions for patients with coronary artery disease (CAD).

The device minimizes vascular complications while providing real-time monitoring of pump performance. Targeted primarily at hospitals and healthcare facilities in the US, Supira Medical aims to expand its market reach internationally as clinical studies advance, serving cardiologists and medical professionals treating patients at heightened cardiac risk. Supira Medical generates revenue through partnerships with hospitals and healthcare systems that employ their pVADs in clinical scenarios. The company's financial model relies on direct sales of these devices for critical care procedures, with revenue derived from one-time equipment sales and potential follow-on support services for device maintenance.

Their pVAD technology is acknowledged for its innovative approach and aligns with value-based healthcare pricing structures, reflecting the clinical benefits provided to healthcare institutions. In March 2025, Supira Medical, Inc. secured USD 120. 00 mn in Series E funding, co-led by Novo Holdings and Qatar Investment Authority, with contributions from returning investors.

This funding will be utilized to expand clinical programs related to high-risk percutaneous coronary interventions and cardiogenic shock. The company is actively designing new products to enhance its portfolio, with plans to introduce additional pVAD models targeting both domestic and international markets by late 2025. The strategic application of the recent funding aims to accelerate their development efforts and broaden their market presence.